semaglutide on shortage list fda status january 2025 Federal judge upholds FDA's removal of Ozempic, Wegovy from drug GLP-1 No Longer FDA's – FDA Ends Semaglutide Shortage Listing,

These adaptations persist even after weight loss stabilizes, creating a biological drive to return to the previous weight set point

These minor reactions are common and do not require treatment unless they persist beyond one week or show signs of infection

Carter R, Aldridge S, Page M, Parker S

At higher dosages of ALA, side effects become more frequent

Patient Engagement and Education: Empowering patients with knowledge about their treatment options and how individual differences affect medication response encourages active participation in their care

The baseline characteristics of the two groups were similar, with standardized mean differences of less than 0.1